This morning, CEL-SCI Corp. (CVM-NYSE Amex) announced the completion of its clinical investigator meeting held last week in Prague. The meeting, which included clinical investigators and research associates, medical monitors, quality assurance personnel, and CEL-SCI’s scientific and management teams, was held to provide protocol and Good Clinical Practice (GCP) training in anticipation of the start of CEL-SCI’s upcoming Phase III trial of Multikine^® in advanced primary head and neck cancer. More than 120 participants from nine countries were present to ask questions about clinical trial conduct.

On November 1, 2010, the Pharmaceutical Research and Manufacturers of America (PhRMA) issued a press release discussing new treatments in development for Alzheimer’s disease. Alzheimer’s is a progressive, degenerative brain disease that causes memory loss, personality changes, dementia, and ultimately death. While the greatest risk factor for Alzheimer’s is age—as the majority of patients diagnosed with Alzheimer’s are 65 or older—the disease is not a result of aging. Rather, researchers believe that a combination of genetic, lifestyle, and environmental factors trigger the onset of Alzheimer’s.